Proton therapy for thoracic malignancies: a review of oncologic outcomes

References

• Mohan R, Grosshans D. Proton therapy - present and future. Adv Drug Deliv Rev. 2017;109:26–44.
   PubMed Web of Science ®Google Scholar
• Liu H, Chang JY. Proton therapy in clinical practice. Chin J Cancer. 2011;30:315–326.
   PubMedGoogle Scholar
• Vyfhuis MAL, Onyeuku N, Diwanji T, et al. Advances in proton therapy in lung cancer. Ther Adv Respir Dis. 2018;12:1753466618783878.
   Web of Science ®Google Scholar
• Szeto YZ, Witte MG, van Kranen SR, et al. Effects of anatomical changes on pencil beam scanning proton plans in locally advanced NSCLC patients. Radiother Oncol. 2016;120:286–292.
   PubMed Web of Science ®Google Scholar
• Mori S, Dong L, Starkschall G, et al. A serial 4DCT study to quantify range variations in charged particle radiotherapy of thoracic cancers. J Radiat Res. 2014;55:309–319.
   PubMed Web of Science ®Google Scholar
• Dowdell S, Grassberger C, Sharp G, et al. Fractionated lung IMPT treatments: sensitivity to setup uncertainties and motion effects based on single-field homogeneity. Technol Cancer Res Treat. 2016;15:689–696.
   PubMed Web of Science ®Google Scholar
• Santiago A, Fritz P, Mühlnickel W, et al. Changes in the radiological depth correlate with dosimetric deterioration in particle therapy for stage I NSCLC patients under high frequency jet ventilation. Acta Oncol. 2015;54:1631–1637.
   PubMed Web of Science ®Google Scholar
• Dowdell S, Grassberger C, Sharp GC, et al. Interplay effects in proton scanning for lung: a 4D Monte Carlo study assessing the impact of tumor and beam delivery parameters. Phys Med Biol. 2013;58:4137–4156.
   PubMed Web of Science ®Google Scholar
• Kang M, Huang S, Solberg TD, et al. A study of the beam-specific interplay effect in proton pencil beam scanning delivery in lung cancer. Acta Oncol. 2017;56:531–540.
   PubMed Web of Science ®Google Scholar
• Poulsen PR, Eley J, Langner U, et al. Efficient interplay effect mitigation for proton pencil beam scanning by spot-adapted layered repainting evenly spread out over the full breathing cycle. Int J Radiat Oncol Biol Phys. 2018;100:226–234.
   PubMed Web of Science ®Google Scholar
• Kardar L, Li Y, Li X, et al. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Pract Radiat Oncol. 2014;4:e259–68.
   PubMedGoogle Scholar
• Diwanji TP, Mohindra P, Vyfhuis M, et al. Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. Transl Lung Cancer Res. 2017;6:131–147.
   PubMed Web of Science ®Google Scholar
• Molitoris JK, Diwanji T, Snider JW 3rd, et al. Advances in the use of motion management and image guidance in radiation therapy treatment for lung cancer. J Thorac Dis. 2018;10:S2437–s50.
   PubMed Web of Science ®Google Scholar
• Higgins KA, O’Connell K, Liu Y, et al. National cancer database analysis of proton versus photon radiation therapy in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;97:128–137.
   PubMed Web of Science ®Google Scholar
• Wang XS, Shi Q, Williams LA, et al. Prospective study of patient-reported symptom burden in patients with non-small-cell lung cancer undergoing proton or photon chemoradiation therapy. J Pain Symptom Manage. 2016;51:832–838.
   PubMed Web of Science ®Google Scholar
• Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1087–1096.
   PubMed Web of Science ®Google Scholar
• Kesarwala AH, Ko CJ, Ning H, et al. Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study. Clin Lung Cancer. 2015;16:237–244.
   PubMed Web of Science ®Google Scholar
• Berman AT, Teo BK, Dolney D, et al. An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer. Radiat Oncol. 2013;8:144.
   PubMed Web of Science ®Google Scholar
• Welsh J, Amini A, Ciura K, et al. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim. 2013;38:442–447.
   PubMed Web of Science ®Google Scholar
• Roelofs E, Engelsman M, Rasch C, et al. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol. 2012;7:165–176.
   PubMed Web of Science ®Google Scholar
• Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20:494–503.
   PubMed Web of Science ®Google Scholar
• Nyman J, Hallqvist A, Lund J, et al. SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol. 2016;121:1–8.
   PubMed Web of Science ®Google Scholar
• Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–1631.
   PubMed Web of Science ®Google Scholar
• Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839.
   PubMed Web of Science ®Google Scholar
• Verma V, Shostrom VK, Zhen WN, et al. Influence of fractionation scheme and tumor location on toxicities after stereotactic body radiation therapy for large (≥ 5 cm) non-small cell lung cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2017;97:778–785.
   PubMed Web of Science ®Google Scholar
• Bush DA, Cheek G, Zaheer S, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys. 2013;86:964–968.
   PubMed Web of Science ®Google Scholar
• Bush DA, Slater JD, Shin BB, et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004;126:1198–1203.
   PubMed Web of Science ®Google Scholar
• Chang JY, Zhang W, Komaki R, et al. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol. 2017;122:274–280.
   PubMed Web of Science ®Google Scholar
• Chi A, Chen H, Wen S, et al. Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis. Radiother Oncol. 2017;123:346–354.
   PubMed Web of Science ®Google Scholar
• Speirs CK, DeWees TA, Rehman S, et al. Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer. J Thorac Oncol. 2017;12:293–301.
   PubMed Web of Science ®Google Scholar
• Nguyen QN, Ly NB, Komaki R, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol. 2015;115:367–372.
   PubMed Web of Science ®Google Scholar
• Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011;117:4707–4713.
   PubMed Web of Science ®Google Scholar
• Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011;117:3004–3013.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Henderson R, Pham D, et al. A phase 2 trial of concurrent chemotherapy and proton therapy for stage III non-small cell lung cancer: results and reflections following early closure of a single-institution study. Int J Radiat Oncol Biol Phys. 2016;95:517–522.
   PubMed Web of Science ®Google Scholar
• Nakayama H, Satoh H, Sugahara S, et al. Proton beam therapy of Stage II and III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81:979–984.
   PubMedGoogle Scholar
• Oshiro Y, Mizumoto M, Okumura T, et al. Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2012;7:370–375.
   PubMed Web of Science ®Google Scholar
• Hatayama Y, Nakamura T, Suzuki M, et al. Preliminary results of proton-beam therapy for stage III non-small-cell lung cancer. Curr Oncol. 2015;22:e370–5.
   PubMed Web of Science ®Google Scholar
• Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:1813–1822.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Nichols RC, Flampouri S, et al. Hypofractionated proton therapy with concurrent chemotherapy for locally advanced non-small cell lung cancer: a phase 1 trial from the university of florida and proton collaborative group. Int J Radiat Oncol Biol Phys. 2020;107:455–461.
   PubMed Web of Science ®Google Scholar
• Wang EH, Corso CD, Rutter CE, et al. Postoperative radiation therapy is associated with improved overall survival in incompletely resected Stage II and III non-small-cell lung cancer. J Clin Oncol. 2015;33:2727–2734.
   PubMed Web of Science ®Google Scholar
• Robinson CG, Patel AP, Bradley JD, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the national cancer data base. J Clin Oncol. 2015;33:870–876.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys. 2008;72:695–701.
   PubMed Web of Science ®Google Scholar
• Le Pechoux C, Pourel N, Barlesi F, et al. LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683. Ann Oncol. 2020;31:S1178.
   PubMed Web of Science ®Google Scholar
• Remick JS, Schonewolf C, Gabriel P, et al. First clinical report of proton beam therapy for postoperative radiotherapy for non-small-cell lung cancer. Clin Lung Cancer. 2017;18:364–371.
   PubMed Web of Science ®Google Scholar
• Vyfhuis MAL, Rice S, Remick J, et al. Reirradiation for locoregionally recurrent non-small cell lung cancer. J Thorac Dis. 2018;10:S2522–s36.
   PubMed Web of Science ®Google Scholar
• Cetingoz R, Arican-Alicikus Z, Nur-Demiral A, et al. Is re-irradiation effective in symptomatic local recurrence of non small cell lung cancer patients? A single institution experience and review of the literature. J buon. 2009;14:33–40.
   PubMed Web of Science ®Google Scholar
• Ebara T, Tanio N, Etoh T, et al. Palliative re-irradiation for in-field recurrence after definitive radiotherapy in patients with primary lung cancer. Anticancer Res. 2007;27:531–534.
   PubMed Web of Science ®Google Scholar
• McAvoy SA, Ciura KT, Rineer JM, et al. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. 2013;109:38–44.
   PubMed Web of Science ®Google Scholar
• Chao HH, Berman AT, Simone CB 2nd, et al. Multi-institutional prospective study of reirradiation with proton beam radiotherapy for locoregionally recurrent non-small cell lung cancer. J Thorac Oncol. 2017;12:281–292.
   PubMed Web of Science ®Google Scholar
• Ho JC, Nguyen QN, Li H, et al. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol. 2018;8:58–65.
   PubMed Web of Science ®Google Scholar
• Badiyan SN, Rutenberg MS, Hoppe BS, et al. Clinical outcomes of patients with recurrent lung cancer reirradiated with proton therapy on the proton collaborative group and university of florida proton therapy institute prospective registry studies. Pract Radiat Oncol. 2019;9:280–288.
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–2084.
   PubMed Web of Science ®Google Scholar
• Lin SH, Wang L, Myles B, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84:1078–1085.
   PubMed Web of Science ®Google Scholar
• Lin SH, Zhang N, Godby J, et al. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer. 2016;122:917–928.
   PubMed Web of Science ®Google Scholar
• Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis. Int J Radiat Oncol Biol Phys. 2017;99:667–676.
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Xu C, Yang J, et al. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. Radiother Oncol. 2017;125:48–54.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao KL, Guerrero TM, et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2008;72:278–287.
   PubMed Web of Science ®Google Scholar
• Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013;86:885–891.
   PubMed Web of Science ®Google Scholar
• Davuluri R, Jiang W, Fang P, et al. Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2017;99:128–135.
   PubMed Web of Science ®Google Scholar
• Fang P, Shiraishi Y, Verma V, et al. Lymphocyte-sparing effect of proton therapy in patients with esophageal cancer treated with definitive chemoradiation. Int J Part Ther. 2018;4:23–32.
   PubMedGoogle Scholar
• Lin SH, Hobbs BP, Verma V, et al. Randomized Phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol. 2020;38:1569–1579.
   PubMed Web of Science ®Google Scholar
• Hong L, Huang Y-X, Zhuang Q-Y, et al. Survival benefit of re-irradiation in esophageal cancer patients with locoregional recurrence: a propensity score-matched analysis. Radiat Oncol. 2018;13:171.
   PubMed Web of Science ®Google Scholar
• DeCesaris CM, McCarroll R, Mishra MV, et al. Assessing outcomes of patients treated with re-irradiation utilizing proton pencil-beam scanning for primary or recurrent malignancies of the esophagus and gastroesophageal junction. J Thorac Oncol. 2020;15:1054–1064.
   PubMed Web of Science ®Google Scholar
• Fernandes A, Berman AT, Mick R, et al. A prospective study of proton beam reirradiation for esophageal cancer. Int J Radiat Oncol Biol Phys. 2016;95:483–487.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Akerley W, Borghaei H, et al. Malignant pleural mesothelioma. J Natl Compr Canc Netw. 2012;10:26–41.
   PubMed Web of Science ®Google Scholar
• Wald O, Sugarbaker DJ. New concepts in the treatment of malignant pleural mesothelioma. Annu Rev Med. 2018;69:365–377.
   PubMed Web of Science ®Google Scholar
• Verma V, Ahern CA, Berlind CG, et al. National cancer database report on pneumonectomy versus lung-sparing surgery for malignant pleural mesothelioma. J Thorac Oncol. 2017;12:1704–1714.
   PubMed Web of Science ®Google Scholar
• Friedberg JS, Simone CB 2nd, Culligan MJ, et al. Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Ann Thorac Surg. 2017;103:912–919.
   PubMed Web of Science ®Google Scholar
• Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–6, 6.e1–3.
   PubMed Web of Science ®Google Scholar
• Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–795.
   PubMed Web of Science ®Google Scholar
• Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84:1685–1692, discussion 92-3.
   PubMed Web of Science ®Google Scholar
• Rosenzweig KE, Zauderer MG, Laser B, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2012;83:1278–1283.
   PubMed Web of Science ®Google Scholar
• Minatel E, Trovo M, Polesel J, et al. Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung. J Thorac Oncol. 2012;7:1862–1866.
   PubMed Web of Science ®Google Scholar
• Chance WW, Rice DC, Allen PK, et al. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys. 2015;91:149–156.
   PubMed Web of Science ®Google Scholar
• Rimner A, Zauderer MG, Gomez DR, et al. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol. 2016;34:2761–2768.
   PubMed Web of Science ®Google Scholar
• Krayenbuehl J, Hartmann M, Lomax AJ, et al. Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy. Int J Radiat Oncol Biol Phys. 2010;78:628–634.
   PubMed Web of Science ®Google Scholar
• Lorentini S, Amichetti M, Spiazzi L, et al. Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment. Strahlenther Onkol. 2012;188:216–225.
   PubMed Web of Science ®Google Scholar
• Pan HY, Jiang S, Sutton J, et al. Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series. Pract Radiat Oncol. 2015;5:e345–53.
   PubMed Web of Science ®Google Scholar
• Li YR, Alley EW, Friedberg JS et al. Prospective assessment of proton therapy for malignant pleural mesothelioma. 16th World Conference on Lung Cancer; Denver, CO 2015.
   Google Scholar
• Rice SR, Li YR, Busch TM, et al. A novel prospective study assessing the combination of photodynamic therapy and proton radiation therapy: safety and outcomes when treating malignant pleural mesothelioma. Photochem Photobiol. 2019;95:411–418.
   PubMed Web of Science ®Google Scholar
• Lee H, Zeng J, Bowen SR, et al. Proton therapy for malignant pleural mesothelioma: a three case series describing the clinical and dosimetric advantages of proton-based therapy. Cureus. 2017;9:e1705.
   PubMed Web of Science ®Google Scholar
• Davis RD Jr., Oldham HN Jr., Sabiston DC Jr. Primary cysts and neoplasms of the mediastinum: recent changes in clinical presentation, methods of diagnosis, management, and results. Ann Thorac Surg. 1987;44:229–237.
   PubMed Web of Science ®Google Scholar
• Network NCC Thymomas and thymic carcinoma (Version 1.2020). Accessed October 3, 2020. https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf.
   Google Scholar
• Barsky AR, Kim MM, Williams GR, et al. Proton-beam therapy: at the heart of cardiac dose-sparing in mediastinal radiotherapy for thymic carcinoma. J Thorac Oncol. 2020;15:1240–1242.
   PubMed Web of Science ®Google Scholar
• Haefner MF, Verma V, Bougatf N, et al. Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma. Acta Oncol. 2018;57:1713–1720.
   PubMed Web of Science ®Google Scholar
• Vogel J, Lin L, Litzky LA, et al. Predicted rate of secondary malignancies following adjuvant proton versus photon radiation therapy for thymoma. Int J Radiat Oncol Biol Phys. 2017;99:427–433.
   PubMed Web of Science ®Google Scholar
• Mercado CE, Hartsell WF, Simone CB 2nd, et al. Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the proton collaborative group and the university of Florida prospective registries. Acta Oncol. 2019;58:1036–1040.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Hoppe BS, Flampouri S, et al. Rationale and early outcomes for the management of thymoma with proton therapy. Transl Lung Cancer Res. 2018;7:106–113.
   PubMed Web of Science ®Google Scholar
• Parikh RR, Rhome R, Hug E, et al. Adjuvant Proton Beam Therapy in the Management of Thymoma: A Dosimetric Comparison and Acute Toxicities. Clin Lung Cancer. 2016;17:362–366.
   PubMed Web of Science ®Google Scholar
• Vogel J, Berman AT, Lin L, et al. Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: early response and toxicity assessment. Radiother Oncol. 2016;118:504–509.
   PubMed Web of Science ®Google Scholar
• Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the childhood cancer survivor study. Blood. 2011;117:1806–1816.
   PubMed Web of Science ®Google Scholar
• van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129:2257–2265.
   PubMed Web of Science ®Google Scholar
• Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. Jama. 2003;290:465–475.
   PubMed Web of Science ®Google Scholar
• Tseng YD, Cutter DJ, Plastaras JP, et al. Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) lymphoma subcommittee. Int J Radiat Oncol Biol Phys. 2017;99:825–842.
   PubMed Web of Science ®Google Scholar
• Andolino DL, Hoene T, Xiao L, et al. Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin’s lymphoma in female pediatric patients. Int J Radiat Oncol Biol Phys. 2011;81:e667–71.
   PubMed Web of Science ®Google Scholar
• Edvardsson A, Kügele M, Alkner S, et al. Comparative treatment planning study for mediastinal Hodgkin’s lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy. Acta Oncol. 2019;58:95–104.
   PubMed Web of Science ®Google Scholar
• Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood. 2018;132:1635–1646.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;84:449–455.
   PubMed Web of Science ®Google Scholar
• Toltz A, Shin N, Mitrou E, et al. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy’s potential. J Appl Clin Med Phys. 2015;16:167–178.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Flampouri S, Zaiden R, et al. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study. Int J Radiat Oncol Biol Phys. 2014;89:1053–1059.
   PubMed Web of Science ®Google Scholar
• Mohindra P, Tseng YD, Badiyan SN, et al. Proton Therapy for Lymphoma: A Multi-institutional Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2017;99:E433.
   Web of Science ®Google Scholar
• Hoppe BS, Hill-Kayser CE, Tseng YD, et al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Ann Oncol. 2017;28:2179–2184.
   PubMed Web of Science ®Google Scholar
• Mohindra P, Mossahebi S, Moreau JM, et al. First clinical experience of gated voluntary breath-hold intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2019;105:S252.
   Web of Science ®Google Scholar
• Tseng YD, Hoppe BS, Miller D, et al. Rates of toxicity and outcomes after mediastinal proton therapy for relapsed/refractory lymphoma. Int J Radiat Oncol Biol Phys. 2017;99:S62–S3.
   Web of Science ®Google Scholar
• McCusker MG, Scilla KA, Simone CB 2nd, et al. Proton beam therapy and immune checkpoint inhibitors in malignant pleural mesothelioma. J Thorac Oncol. 2019;14:e185–e7.
   PubMedGoogle Scholar